In adults, insulin glargine (a long-acting insulin analog) reduces the risk of nocturnal hypoglycemia and improves control of morning blood glucose levels; however, most published studies included ...
Objective — To determine the pharmacokinetic and pharmacodynamic dose-response effects of insulin glargine administered subcutaneously in individuals with type 2 diabetes. Research design and ...
The Europe-wide approval is the first ever insulin treatment licensed through the European Medicines Agency's biosimilar pathway, and the fourth diabetes product approved in the EU from the Lilly ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback